 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2470 | 回復(fù): 4 | |||
| 本帖產(chǎn)生 1 個(gè) 博學(xué)EPI ，點(diǎn)擊這里進(jìn)行查看 | |||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | |||
cclandrover新蟲 (初入文壇)
|
[求助]
求最新cell雜志旗下的chemistry and biology 的格式和各種要求
|
||
| 求最新cell雜志旗下的chemistry and biology 雜志的格式和各種要求，麻煩各位了 我這面就是打不開官網(wǎng)，謝謝啦 |
回復(fù)此樓» 猜你喜歡
085600材料與化工
已經(jīng)有6人回復(fù)
-
281求調(diào)劑（0805）
已經(jīng)有24人回復(fù)
-
265求調(diào)劑
已經(jīng)有8人回復(fù)
-
0817 化學(xué)工程 299分求調(diào)劑 有科研經(jīng)歷 有二區(qū)文章
已經(jīng)有21人回復(fù)
-
295材料求調(diào)劑，一志愿武漢理工085601專碩
已經(jīng)有4人回復(fù)
-
0856調(diào)劑，是學(xué)校就去
已經(jīng)有9人回復(fù)
-
298-一志愿中國(guó)農(nóng)業(yè)大學(xué)-求調(diào)劑
已經(jīng)有9人回復(fù)
-
求調(diào)劑
已經(jīng)有4人回復(fù)
-
學(xué)校已經(jīng)提交到NSFC，還能修改嗎？
已經(jīng)有7人回復(fù)
-
材料學(xué)碩297已過四六級(jí)求調(diào)劑推薦
已經(jīng)有6人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- Physical Biology of the Cell
已經(jīng)有73人回復(fù)
- SCI期刊最新影響因子——2014年發(fā)布
已經(jīng)有7人回復(fù)
- 天然藥化重量級(jí)著作：Comprehensive-Natural-Products-II-Chemistry-and-Biology
已經(jīng)有144人回復(fù)
- Biotechnology and Applied Biochemistry 投稿經(jīng)驗(yàn)
已經(jīng)有5人回復(fù)
- Journal of Agricultural and Food Chemistry雜志投稿狀態(tài)
已經(jīng)有31人回復(fù)
- 關(guān)于Journal of Agricultural and Food Chemistry格式修改
已經(jīng)有9人回復(fù)
- analytical and bioanalytical chemistry格式要求
已經(jīng)有7人回復(fù)
- cancer research 投稿要求
已經(jīng)有10人回復(fù)
- 投Computational Biology and Chemistry后，這是怎么啦？
已經(jīng)有5人回復(fù)
- 介紹一種包含很多學(xué)科的SCI期刊
已經(jīng)有22人回復(fù)
- 求牛人幫忙寫一段COVER LETTER里面的一段話，謝謝！
已經(jīng)有7人回復(fù)
- 求助：Anti-Cancer Agents in Medicinal Chemistry雜志的要求及格式。
已經(jīng)有5人回復(fù)
- Current Protocols in Cell Biology
已經(jīng)有86人回復(fù)
- Current Protocols in Cell Biology (Wiley, 2004) .pdf
已經(jīng)有32人回復(fù)
- FOOD CHEMISTRY投稿格式相關(guān)要求
已經(jīng)有11人回復(fù)
下裡巴人
金蟲 (小有名氣)
- 博學(xué)EPI: 1
- 應(yīng)助: 4 (幼兒園)
- 金幣: 937.6
- 紅花: 1
- 帖子: 84
- 在線: 95.3小時(shí)
- 蟲號(hào): 1382419
- 注冊(cè): 2011-08-28
- 性別: GG
- 專業(yè): 催化化學(xué)
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★
cclandrover: 金幣+10, 博學(xué)EPI+1, ★★★★★最佳答案 2015-03-09 12:41:44
cclandrover: 金幣+10, 博學(xué)EPI+1, ★★★★★最佳答案 2015-03-09 12:41:44
|
不知道是不是這個(gè) 沒發(fā)現(xiàn)哪有下載的鏈接，就直接給你復(fù)制了。 Information for Authors Chemistry & Biology publishes research articles and review material of general interest to chemical biology community, and to the broader life science community. Launched in September 1994 (a "pre-launch" issue appeared in April 1994), Chemistry & Biology publishes 12 issues a year. Chemistry & Biology has four Editors, active research scientists, who work in concert with a PhD-trained scientific editor located in the Cell Press offices to ensure rapid peer review of cutting edge work. All the content published in Chemistry & Biology, back to January 1995, is freely available starting 12 months after publication. Editorial Evaluation Timeline All submissions are initially evaluated in depth by the editors. Papers that are not deemed by the editors to be strong candidates for publication will be returned to the authors without detailed review, typically within 3–5 days. Otherwise, manuscripts will be sent to reviewers. The editors make every effort to reach decisions on these papers within 3–4 weeks of the submission date. If revisions are a condition of publication, editors will carefully evaluate the reviewers' comments and, whenever possible, will provide guidance on the important concerns to be addressed. We generally allow 2 months for revisions and consider only one revised version of the paper. Evaluations of conceptual advance and significance are made based on the literature available on the day of the final decision, not the day of submission. Accepted papers will be published in print within 3 months of acceptance and, in most cases, within 4–5 weeks online ahead of the print issue. Any major changes after acceptance are subject to review and may delay publication. Presubmission Inquiries If you would like editorial input on whether your paper might be a strong candidate for consideration at Chemistry & Biology, you can send a presubmission inquiry. This should include an abstract plus a brief description of the results and an explanation of the interest and significance to the broad readership of Chemistry & Biology and should be e-mailed to chembiol@cell.com. We try to respond to these within 2–5 days. Status Inquiries Editorial Manager, the online manuscript submission system used by Cell Press journals, posts different status updates as it progresses through the editorial process. You may also e-mail chembiol@cell.com or call +1 617 386 2128 with specific questions. Relationship between Cell Press Journals Cosubmission In the limited number of instances in which a paper is potentially appropriate in scope for the readership of two different Cell Press titles, the Cell Press journals offer authors a unique opportunity not provided by any other journal group to submit a manuscript for joint consideration at two journals at the same time. Authors interested in pursuing this option should contact the editors of both journals for further information. Transfer of Papers between Cell Press Journals Each Cell Press journal is editorially independent. Cell Press has developed a manuscript transfer system designed to provide maximal flexibility, efficiency, and control for the authors. If a paper is reviewed and rejected at one Cell Press journal, the author can request that the editor make the reviews and reviewer identities available to the editor of another Cell Press journal. Authors interested in pursuing this option should e-mail the editor of the second Cell Press journal directly. In many cases, the second editor will be able to reach a decision based on the advice of these reviewers. In some cases, the editor may need to seek comments from additional reviewers. The authors are also free to submit the paper to another Cell Press title without mentioning the first review process, in which case the manuscript will be evaluated by the editor and, as appropriate, reviewed independently without reference to the original reviews. Editorial Policies Manuscripts are considered with the understanding that no part of the work has been published previously in print or electronic format and the paper is not under consideration by another publication or electronic medium. If you have questions about whether posting a manuscript or data that you plan to submit to this journal on an openly available preprint server or poster repository would affect consideration, we encourage you to contact the editors so that we may provide more specific guidance. In many cases, posting will be possible. All in press or submitted works that are pertinent to the manuscript under consideration by the journal (including those cited in the manuscript under consideration) must accompany the submission. Related manuscripts that have been submitted elsewhere during the period of revision must accompany revised manuscripts. Failure to provide copies of related manuscripts under consideration elsewhere may delay the review process and may be grounds for rejection. Under no circumstances will any paper be considered that contains any data that have been submitted for publication elsewhere. Authorship Corresponding Author: The corresponding author(s) is responsible for ensuring that all appropriate contributors are listed as authors and that all authors have agreed to the manuscript's content and its submission to Chemistry & Biology. In a case where we become aware of an authorship dispute, authorship must be approved in writing by all of the parties. The corresponding author(s) is also responsible for ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication. Because of the responsibilities associated with this designation, a maximum of two corresponding authors is allowed. Exceptions will only be considered in cases of compelling need and by prior discussion with the editors. Co-authorship Designations: In recognition of increasingly collaborative studies, up to two additional co-senior authors may be designated. All co-senior authors will be identified by a numeric footnote in the affiliations list, e.g., "5Co-senior author". Beyond co-senior and corresponding author designations (see above), co-authorship designations are only permitted for the first author position. There is no limitation on the number of authors that can be designated as co-first authors, but a description of each author's specific contribution must be provided in the Author Contributions section of the manuscript. All co-first authors will be identified by a numeric footnote in the affiliations list, e.g., "4Co-first author". As the complexity and interdisciplinary nature of science grows and evolves, so do the networks of collaborations both within and between labs for published articles. While the author list at the start of a manuscript is not an appropriate or sufficient place to convey this increasingly complex information, all authors are encouraged to include the detailed information about the specific contributions of each author and laboratory in the Author Contributions section. For more information, please see "Author Contributions" under "Preparation of Specific Sections." Conflict of Interest Cell Press requires all authors to disclose any financial conflict of interest that might be construed to influence the results or interpretation of their manuscript. Authors must declare any such conflict in the cover letter accompanying the manuscript and in the Acknowledgments section of the manuscript itself. The corresponding author will be asked to sign a form on behalf of all of the authors regarding potential conflicts of interest at the time of acceptance. As a guideline, any affiliation associated with a payment or financial benefit exceeding $10,000 p.a. or 5% ownership of a company or research funding by a company with related interests would constitute a conflict that must be declared. This policy applies to all submitted research manuscripts and review material. Examples of statement language include: "AUTHOR is an employee and shareholder of COMPANY"; "AUTHOR is a founder of COMPANY and a member of its scientific advisory board"; "This work was supported in part by a grant from COMPANY." Studies Involving Humans and Animals For manuscripts reporting studies involving human subjects, statements identifying the committee approving the studies and confirming that informed consent was obtained from all subjects must appear in the Experimental Procedures section. All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant institutional and national guidelines and regulations. In the manuscript, a statement identifying the committee approving the experiments and confirming that all experiments conform to the relevant regulatory standards must be included in the Experimental Procedures section. The editors reserve the right to seek comments from reviewers or additional information from authors on any cases in which concerns arise. We suggest that researchers carrying out experiments with animals refer to the ARRIVE guidelines and recommendations from an NIH-sponsored workshop regarding experimental design and reporting standards. Data Processing Policy Authors should make every attempt to reduce the amount of postacquisition processing of data. Some degree of processing may be unavoidable in certain instances and is permitted provided that the final data accurately reflect that of the original. In the case of image processing, alterations must be applied to the entire image (e.g., brightness, contrast, color balance). In rare instances for which this is not possible (e.g., alterations to a single color channel on a microscopy image), any alterations must be clearly stated in the figure legend and in the Experimental Procedures section. Groupings and consolidation of data (e.g., cropping of images or removal of lanes from gels and blots) must be made apparent and should be explicitly indicated in the appropriate figure legends. Data comparisons should only be made from comparative experiments, and individual data should not be utilized across multiple figures. In cases in which data are used multiple times (e.g., multiple experiments were performed simultaneously with a single control experiment), this must be clearly stated within each figure legend. In the event that it is deemed necessary for proper evaluation of the manuscript, authors will be required to make the original unprocessed data available to the editors of the journal. Chemical Compounds If a paper reports new chemical entities, the authors are required to provide the exact structures of the compounds and are encouraged to include appropriate data to support the assignment of each chemical structure reported according to set standards in the field. Papers reporting the synthesis of new molecules must include the details of the synthesis in the Experimental Procedures. We encourage authors to submit their small-molecule crystallographic data to Cambridge Structural Database (CSD) and to deposit all appropriate information to PubChem. In both cases, appropriate database IDs should be included in the final version of the manuscript. When a paper reports a new chemical entity or use of a known compound, the authors should use systematic nomenclature to refer to the chemical compounds, based on the guidelines of the International Union of Pure and Applied Chemistry (IUPAC). Use of informal common names, such as rapamycin, cholesterol, and penicillin, is also acceptable. Any standard or unconventional abbreviation should be defined at the point where it first occurs in the text. For graphical representation of chemical structures, we suggest that authors refer to the IUPAC recommendations. There are a range of available molecular editor programs for creating images of chemical structures. Regardless of the program used, when inserting chemical structures into figures and/or tables, please ensure that they are exported from the molecular editor program as high-resolution files and that the final figure/table files follow general Cell Press Figure Guidelines). Distribution of Materials and Data One of the terms and conditions of publishing with Cell Press is that authors be willing to distribute any materials and protocols used in the published experiments to qualified researchers for their own use. Materials include but are not limited to cells, DNA, antibodies, reagents, organisms, and mouse strains or, if necessary, the relevant ES cells. These must be made available with minimal restrictions and in a timely manner, but it is acceptable to request reasonable payment to cover the cost of maintenance and transport of materials. If there are restrictions to the availability of any materials, data, or information, these must be disclosed in the cover letter and in the Experimental Procedures section of the manuscript at the time of submission. Data sets must be made freely available to readers from the date of publication and must be provided to editors and peer reviewers at submission for the purposes of evaluating the manuscript. For the following types of data, submission of the full data set to a community-endorsed, public repository is mandatory. Accession numbers must be provided in the paper (see "Database Linking" below for specific formatting instructions). Examples of appropriate public repositories are listed below. DNA and Protein Sequences Protein Sequences: Uniprot DNA and RNA Sequences: Genbank/European Nucleotide Archive (ENA)/DDBJ, Protein DataBank, UniProt DNA Sequencing Data (traces and short reads): NCBI Trace and Short-Read Archive, ENA's Sequence Read Archive Deep Sequencing Data: Deposit in GEO or ArrayExpress upon submission to the journal The sequences of all RNAi, antisense, and morpholino probes must be included in the paper or deposited in a public database with the accession number provided in the paper. Human genomic data reporting newly described SNPs and CNVs identified in control samples should be deposited in an appropriate repository such as dbSNP, the Database of Genomic Variants Archive (DGVa), or the Database of Genomic Structural Variation (dbVAR). We encourage but do not require the deposition of human sequence data in an appropriate repository such as dbGaP. We expect that, if data collected for a published paper cannot be included in the paper or made accessible in a public repository, then authors will accommodate legitimate requests for sharing of human genetics data provided that there are no IRB restrictions. Structures of Biological Macromolecules The atomic coordinates and related experimental data (structure factor amplitudes/intensities and/or NMR restraints) must be deposited at a member site of the Worldwide Protein Data Bank. Electron microscopy-derived density maps must be deposited into the EMDB through one of the partner sites (Protein Data Bank in Europe or EMDataBank). Atomic coordinates fitted to EM maps must also be deposited to a wwPDB member site. The corresponding database IDs must be included in the manuscript. Authors must agree to release the atomic coordinates and experimental data when the associated article is published. Additionally, Cell Press now recommends that authors include the PDB validation report as part of the Supplemental Information for all new submissions describing results of X-ray and NMR structure determination. Microarray Data MIAME-Compliant Microarray Data: GEO or ArrayExpress upon submission to the journal Data must be MIAME compliant, as described at the MGED website specifying microarray standards. Other Data Sets In addition to the information that must be deposited in public databases as detailed above, authors are encouraged to contribute additional information to the appropriate databases. Authors are also encouraged to deposit materials used in their studies in the appropriate repositories for distribution to researchers. Examples of repositories that facilitate sharing large data sets, including some that offer the option of anonymous referee access to data before publication, include: For proteomics data: PRIDE, PeptideAtlas For protein interaction data: IMEx consortium of databases, including DIP, IntAct, and MINT For chemical compound screening and assay data: PubChem If your paper makes use of genomic data generated from HeLa cells, we encourage you to comply with the NIH HeLa Genome Data Use Agreement by affirming that the NIH has approved use of the data and acknowledging the contributions of Henrietta Lacks and her family to the research. Where there is no public repository and if the data sets are too large to submit to the journal online, authors should either consult the journal editorial office for advice or provide five separate copies of these data to the editors in an appropriate format (for example, CD or DVD) for the purposes of peer review. Database Linking Cell Press encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: "Database: xxxx" for single accession numbers and "Database: xxxx, yyyy, zzzz" for multiple accession numbers (e.g., "Genbank: NM_000492"; "GEO: GSE6364"; "PDB: 1TUP, 1KW4, 3H5X"  . See https://www.elsevier.com/about/c ... on/database-linking for more information and a full list of supported databases. Open Archive Cell Press papers are freely available starting 12 months after publication. Copyright Upon acceptance of an article, authors will be asked to transfer copyright. This transfer will ensure the widest possible dissemination of information. A form facilitating transfer of copyright will be provided upon acceptance of the manuscript. After transfer of copyright, authors retain rights as discussed below. Authors' Rights As an author, you (or your employer or institution) may do the following: Make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use Make copies and distribute such copies (including through e-mail) of the article to known research colleagues for the personal use by such colleagues (but not for commercial purposes, as described below) Post a revised personal version of the final text (including illustrations and tables) of the article (to reflect changes made in the peer review and editing process) on your personal or institutional website or server, with a link (through the relevant DOI) to the article as published, provided that such postings are not for commercial purposes, as described below. Please note: Depositing in or posting to special repositories (such as PubMed Central or institutional repositories) is permitted only under specific agreements between Elsevier and the repository and only when consistent with Elsevier's policies concerning such repositories. Present the article at a meeting or conference and distribute copies of the article to the delegates attending such meeting Allow your employer to use all or part of the information in the article for other intracompany use (e.g., training) if the article is a "work for hire" made within the scope of your employment Retain patent and trademark rights and rights to any process or procedure described in the article Include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially) Use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal) Prepare other derivative works that extend the article into book-length form or otherwise re-use portions or excerpts in other works, with full acknowledgment of its original publication in the journal All copies (print or electronic) or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal. However, you should not indicate in the citation that the version that you are reproducing or posting is the final published version as published in the journal. For example, it may be appropriate to indicate, "This paper has been submitted to [Journal] for consideration." Commercial purposes include: the posting by companies or their employees for use by customers (e.g., pharmaceutical companies and physician prescribers); commercial exploitation such as associating advertising with such posting (including the linking to advertising by search engines); the charging of fees for document delivery or access; or the systematic distribution to others via e-mail lists or list servers (to parties other than known colleagues), whether for a fee or for free. Funding Bodies In compliance with the public access policies of NIH, HHMI, Wellcome Trust, and several other funding bodies, Cell Press deposits accepted, peer-reviewed manuscripts on authors' behalf to PubMed Central (PMC). Please see our Funding Bodies Policies page for complete information. Permissions If you are adapting images or information that you have previously published in a Cell Press journal, there is no need to ask permission to do so (see "Authors' Rights" above); we ask only that you cite the original publication. For information on how to request permission to use previously published work, please see our Permissions page. If excerpts from other copyrighted works are included in your manuscript, you must obtain written permission from the copyright owners and credit the sources in the article. To obtain permission to use material from Cell Press and Elsevier journals and books, e-mail permissions@elsevier.com. If you have adapted a figure from a published figure, please check with the copyright owners to see if permission is required and include a complete citation/reference for the original article. Obtaining permissions can take up to several weeks. As lack of appropriate permissions can delay publication, we recommend that you request permission at the time of submission. Prepublication Publicity Work intended for submission to a Cell Press journal, currently under consideration at a Cell Press journal, or in press at a Cell Press journal may not be discussed with the media before publication. All Cell Press papers will remain under media embargo until 12 PM NOON (US, EST) on their date of publication. Providing preprints, granting interviews, discussing data with members of the media, or participating in press conferences in advance of online publication without prior approval from the Cell Press editorial office may be grounds for rejection. With regards to the scientific literature, papers in press with a Cell Press journal should not be discussed in reviews elsewhere prior to the date of online publication. Authors are welcome to present and discuss material intended for publication with Cell Press at scientific meetings; however, we do require that they refrain from discussing the findings with members of the press beyond those included in the formal presentation. In addition, we encourage meeting organizers to contact our editorial office in advance of a meeting if they have any questions regarding this policy. Any questions or issues regarding prepublication publicity should be directed to Press Officer Mary Beth O'Leary (moleary@cell.com). Interaction with Members of the Press for Papers in Press Authors are free to talk with the press one week prior to online publication, provided any information exchanged is embargoed until 12 PM NOON (US, EST) on the day of online publication. Authors may also discuss their work in press under embargo with other scientific journals for purposes of coverage in review material. Please refer any inquiries from media contacts and other journals to us. If your institutional press office wishes to issue a press release, they should contact us in advance for final embargo information. Any questions or issues regarding interaction with the press should be directed to Press Officer Mary Beth O'Leary (moleary@cell.com). Research Article Formats Research, Resource, and Brief Communication articles are all articles types that are handled through our online submission system, Editorial Manager. A brief description of each article type is provided below. Research Articles Research Articles present conceptual advances of unusual significance regarding a chemical biology question of wide interest. Research papers should be as concise as possible and written in a style that is accessible to the broad Chemistry & Biology readership. The total character count of an article must be under 55,000 (including spaces, references, and figure legends), and there should be no more than seven figures and/or tables. Additional display items may be published online as Supplemental Information at the discretion of the editor (please see the Supplemental Information guidelines for more information). Brief Communication Articles Brief Communications are short research articles reporting high-impact results. Brief Communications should be organized in the same way as Research articles but are limited to a maximum of 25,000 characters and should contain a combined total of no more than four figures and tables. Resource Articles The Resource format is designed to highlight significant technical advances, chemical tool and platform development strategies, and/or major informational databases that are of value and interest to the broad Chemistry & Biology readership. Manuscripts reporting the development of an important technological advance should include a proof-of-principle demonstration that the new methodology or tool will open the door for addressing important questions in a variety of biomedical research areas. Manuscripts reporting a major informational database should propose provocative new biological insights that can be derived from an analysis of the data set. Resources follow the same format and length guidelines as Research articles. Matters Arising Articles The Matters Arising format provides a venue for research papers that directly and definitively challenge the main take-home message of a previously published Chemistry & Biology paper. We reserve this format for cases in which we feel there is an urgent need to alert our readership that the published conclusions require re-examination. It is not the appropriate venue for debates that are part of standard scientific discourse or for advances that reflect a normal evolution of scientific understanding. Revisions will not be permitted, so Matters Arising articles will either be accepted or rejected based on editorial evaluation and/or reviewers' comments, but not returned for further experimental work. Authors of the original paper will be given an opportunity to provide a response to the Matters Arising that will be evaluated editorially and may or may not be reviewed and published together with the Matters Arising. Matters Arising articles follow the same format and length as Research articles. Preparation and Online Submission of Full-Length Articles Chemistry & Biology requires authors to submit manuscripts via our online submission system, Editorial Manager. An author tutorial regarding online submission is available at the Editorial Manager website. Authors may contact the editorial office (chembiol@cell.com or +1 617 386 2128) for assistance. Editorial Manager will prompt you to upload the individual components of your manuscript (cover letter, text, figures, supplemental data, etc.) as separate files. Upon completion of this step, the website will build a composite PDF file of your entire manuscript that will contain links for the editors and reviewers to download the individual high-resolution files of each component. Please note that the version of the PDF file that is accessible to reviewers does not contain the cover letter; any information therein will remain confidential. Please be aware that Editorial Manager will send all communications about the paper (including the request for final approval and the confirmation of submission) to the person who is checked off as corresponding author during the submission process or, if no name is designated, to the person whose account is used to submit the manuscript. If you wish to specify a different author for editorial correspondence after submission, please contact the editorial assistant at chembiol@cell.com. Please note that you will be prompted by the system to provide names of four reviewer suggestions, as well as indicate opposed reviewers. Additionally, please plan to include this information in the cover letter as indicated below. The reviewer names must be accompanied by the current e-mail addresses and a brief description of their expertise. Cover Letter Each submission should be accompanied by a cover letter, which should contain a brief explanation of what was previously known, the conceptual advance provided by the findings, and the significance of the findings to a broad readership. A cover letter should contain suggestions for appropriate reviewers and may include up to three requests for reviewer exclusions. The cover letter is confidential to the editor and will not be seen by reviewers. General Article Organization and Text Specifications Chemistry & Biology full-length articles generally contain the following sections in this order: Title, Authors, Affiliations, Contact Information, Additional Title Page Footnotes, Summary, Introduction, Results, Discussion, Significance, Experimental Procedures, Author Contributions, Acknowledgments, References, Figure and Table Legends, Figures and Tables, Graphical Abstract, and Supplemental Information. The text (title through legends) should be provided as one document, which may also contain the tables. Figures should be provided separately. Supplemental Information should be provided separately. The total character count of the main text, including all sections and including spaces but excluding supplemental data, should not exceed 55,000. An article may contain up to seven figures and/or tables. Gene symbols should be italicized; protein products of the loci are not italicized. Nonstandard abbreviations should be defined when first used in the text. Use of abbreviations should be kept at a minimum. Manuscript file types that we can accept for submission include Word, RTF, PDF, and TXT. Required items differ for each article type and are specified during the submission process. Please note that the text should be double spaced, and pages and lines should be numbered. Although summaries need to be entered as text files separate from the body of the manuscript during the online submission process, they should also be included within the manuscript file as usual. Manuscripts that do not conform to the format guidelines may be returned to the authors for reformatting. Preparation of Specific Sections Title Titles can occupy no more than three lines of type. Each line should contain no more than 50 characters, including spaces. The title should convey the conceptual significance of the paper to a broad readership. Authors/Affiliations Author names should be spelled out rather than set in initials. Authors should be footnoted to corresponding affiliations. Affiliations should contain the following core information: department(s)/subunit(s); institution; city, state/region, postal code; country. Note: Please check author names and affiliations carefully, as we cannot amend or correct these sections after publication. Contact The contact line should include the e-mail address of the corresponding author. The published corresponding author is responsible for ensuring adherence to all editorial and submission policies and for any communications that may result after publication. One corresponding author is preferred, but two are allowed. Additional Footnotes Footnotes are only allowed on page 1 of the text (and in tables). They may include a present address or may indicate co-first or co-senior authorship. For more on designations of author contributions, please see the "Authorship" section above, under Editorial Policies. Summary The Summary consists of a single paragraph of fewer than 150 words. It should clearly convey the conceptual advance and significance of the work to a broad readership. In particular, the Summary should contain a brief background of the question, a description of the results without extensive experimental detail, and a summary of the significance of the findings. References should not be cited in the Summary. Highlights and eTOC Blurb Highlights are a short collection of bullet points that convey the core findings of the article. Specifications: up to four bullet points may be included; the length of an individual bullet point should not exceed 85 characters (including spaces); only the core results of the paper should be covered. The eTOC blurb is a short summary of the main take-home message of the paper and should describe the context and significance of the findings for the broader readership. Please see the "In Brief" links in the Table of Contents for examples. Specifications: This blurb should be 40 words or fewer; this blurb should be written in the third person and refer to “First Author et al.” Both are required for all research papers and will be displayed online with the article; however, they will not appear in print. On the EM page where you are asked to upload your files, please choose "Highlights and eTOC Blurb" and upload a single Word document containing both your Highlights and the eTOC Blurb. Introduction The Introduction should be succinct, with no subheadings, and should present the background information necessary to provide a context for the results. Results This section should be divided with subheadings. Footnotes should not be used. Discussion The Discussion should explain the significance of the results and place them into a broader context. It should not be redundant with the Results section. This section may contain subheadings and can in some cases be combined with the Results section. Significance The Significance consists of a single paragraph of no more than 300 words. The primary goal of the Significance paragraph is to clearly explain the relevance and the significance of the study to the broad readership of Chemistry & Biology. References should not be cited. Experimental Procedures The Experimental Procedures should, at minimum, include enough detail to allow the reader to understand the general experimental design and to be able to assess the data presented in the figures. More detailed protocols and procedures needed for readers to reproduce experiments should be included in the Supplemental Experimental Procedures. Any supplemental tables that list materials used in the study (oligonucleotides, strains, etc.) should be included within the relevant section of the Supplemental Experimental Procedures; these tables should have a title but should not be numbered. If your paper contains Supplemental Experimental Procedures, please make sure that they are referred to within the main Experimental Procedures so that it is clear to the reader that additional details are available online. This section should also include a description of any statistical methods employed in the study. A more detailed version of the procedures and details such as oligo sequences, strains, and specifics of how constructs were made can be included in the Supplemental Information, but it is not appropriate to move the majority of the Experimental Procedures to Supplemental Information in order to shorten the text. Please see our complete Supplemental Information guidelines for more information. Author Contributions We strongly encourage inclusion of a section describing the contributions of each author, designated by initials. For the case of co-first authors, a description of each author’s contribution is required. Acknowledgments This section may acknowledge contributions from non-authors and/or list funding sources, and it should include a statement of any conflicts of interest. Please check this section carefully, as we cannot allow amendments or corrections after publication. References References should include only articles that are published or in press. For references to in press articles, please confirm with the cited journal that the article is in fact accepted and in press and include a DOI number and online publication date. Unpublished data, submitted manuscripts, abstracts, and personal communications should be cited within the text only. Personal communication should be documented by a letter of permission. Submitted articles should be cited as unpublished data, data not shown, or personal communication. Please use the style shown below for references. Note that "et al." should only be used after ten authors. Article in a periodical: Sondheimer, N., and Lindquist, S. (2000). Rnq1: an epigenetic modifier of protein function in yeast. Mol. Cell 5, 163–172. Article in a book: King, S.M. (2003). Dynein motors: Structure, mechanochemistry and regulation. In Molecular Motors, M. Schliwa, ed. (Weinheim, Germany: Wiley-VCH Verlag GmbH), pp. 45–78. An entire book: Cowan, W.M., Jessell, T.M., and Zipursky, S.L. (1997). Molecular and Cellular Approaches to Neural Development (New York: Oxford University Press). Figure Legends Legends should be included in the submitted manuscript as a separate section. Each figure legend should have a brief title that describes the entire figure without citing specific panels, followed by a description of each panel. For any figures presenting pooled data, the measures should be defined in the figure legends (for example, "Data are represented as mean ± SEM." . Each legend should refer to any supporting items in the Supplemental Information (e.g., "See also Figure S1.".Tables When creating a table, please use the Microsoft Word Table function. Tables should include a title, and footnotes and/or legend should be concise. Include tables in the submitted manuscript as a separate section. Tables not created with the Microsoft Word table function will need to be revised by the author. When creating tables, please adhere to the following guidelines: Do not submit tables in Excel or PDF format. Do not place an Excel table in a Word document. Format tables with Word's Table function; do not use tabs or spaces to create a table. Do not use line breaks or spaces to separate data within a cell. Use separate cells for all discrete data elements within a table. Number tables as Table 1, Table 2, Table 3, etc., rather than as Table 1a, Table 1b, Table 1c, etc. If bold or italic font is used within a table to indicate some feature of the data, please give an explanation of its usage in the legend. All abbreviations within a table must be defined in the table legend or footnotes. Footnotes should be listed with superscript lowercase letters, beginning with “a.” Footnotes may not be listed with numbers or symbols. Supplemental Information In general, Supplemental Information is limited to data and other materials that directly support the main conclusions of a paper but cannot be included in the main paper for reasons such as space or file format restrictions. SI should not be used to present data that are preliminary or that conceptually go beyond the main point of the paper. Before submitting your supplemental materials, please refer to our complete instructions in the Supplemental Information guidelines. This page also contains information on submitting movie and other multimedia files. Figures and Graphical Abstracts Digital figure files submitted through Editorial Manager must conform to our digital figure guidelines or authors will be asked to revise them. If you have any questions about digital files, please contact Diana Oesterle, Issue Manager of Chemistry & Biology, at doesterle@cell.com. Graphical Abstract A graphical abstract should allow readers to quickly gain an understanding of the main take-home message of the paper and is intended to encourage browsing, promote interdisciplinary scholarship, and help readers identify more quickly which papers are most relevant to their research interests. Graphical abstracts may be submitted at any stage but are only required once a paper has been accepted for publication (it is not necessary to provide a graphical abstract for a new submission). Graphical abstracts can be uploaded in Editorial Manager by selecting "Graphical Abstract" when uploading files. Refer to our digital figure guidelines for graphical abstract preparation details. Submission of Revised Manuscripts In addition to the sections described above, revised manuscripts must also contain a detailed point-by-point response to the comments of the reviewers and/or editors. The cover letter should briefly summarize how the revised manuscript addresses these comments. In general, revised manuscripts will be reconsidered only if resubmitted within 2 months of the date of the original decision. Checklist for Final Submission 1. Please make sure your final manuscript: Meets our restrictions of 55,000 characters, including spaces, and seven figures and/or tables Includes database accession numbers for new gene sequences, protein sequences, structures, microarray data, or other data (see our Distribution of Materials and Data policy under the Editorial Policies section) Includes explanation of statistical methods and sufficient detail of procedures in the Experimental Procedures section For any figures presenting pooled data, defines the measures in the figure legend 2. Please submit your final materials through Editorial Manager. 3. Please include all of the following when you are resubmitting your final materials: A modifiable electronic version of the final text (Microsoft Word .docx file is preferred) A companion file containing the article Highlights and eTOC blurb High-resolution digital files of the main and supplemental figures in an accepted format (see digital figure guidelines) Supplemental Information set and submitted as outlined in the Supplemental Information guidelines Additional Supplemental Information files such as movies and spreadsheets Highlights Graphical Abstract Signed conflict of interest form (please refer to your Editorial Manager letter for a link to this form) A short paragraph of 50 words describing the context and significance of the findings, to be adapted for e-mail alerts Cover letter Front Matter Formats Submission of Front Matter Articles Most of the front matter material published in Chemistry & Biology is commissioned by the editors. However, proposals for appropriate review material pieces will be considered. Chemistry & Biology publishes the following front matter article types. Minireviews Minireviews discuss a sharply focused scientific topic of interest, usually highlighting emerging themes from papers in the recent literature. Minireviews are limited to 25,000 characters in length (including references, figure legends, and spaces) with no more than four figures. Minireviews are usually commissioned, but suggestions in the form of a one-page summary are welcome and may be sent to the journal's office (chembiol@cell.com) Reviews Chemistry & Biology publishes comprehensive full-length reviews on topics of interest to Chemistry & Biology's broad readership. Reviews follow the same format guidelines as research articles. In addition to a balanced view of the topic, Reviews can provide a new conceptual framework for recent data. Reviews are usually commissioned, but suggestions in the form of a one-page summary are welcome and may be sent to the journal's office (chembiol@cell.com). Perspectives Perspectives are concise opinion pieces that provide fresh insights into published scientific data. They may contain more speculation than traditional formats. Perspectives may also take a historical viewpoint, discussing a landmark paper or a series of papers. Additionally, Perspectives can present a forward thinking view of an emerging topic. Perspectives are 3,000 to 3,500 words in length and with up to four display items (figures and tables). Perspectives are usually commissioned, but suggestions in the form of a one-page summary are welcome and may be sent to the journal's office (chembiol@cell.com). Meeting Reports Chemistry & Biology occasionally publishes reports that present the important themes of a recent conference that has relevance for the journal's readers. Meeting Reports are 2,000 to 4,000 words with 20 or fewer references and one or two figures if appropriate. Previews Previews highlight one or several research papers published in the same issue of Chemistry & Biology or in a recent issue of another journal, placing the results in context for the journal’s broad readership. Previews are 1,000 words in length with no more than 10 references and one or two figures. Most Previews are commissioned, but timely unsolicited contributions will be considered. Production and Proofs After final acceptance, the manuscript will be passed to the production team to be copyedited and prepared for printing. Authors will be charged $500 for the first color figure and $275 for each additional color figure. Figures may be resized during the production process. PDF proofs will arrive via e-mail about 2 weeks prior to publication and must be returned with vital corrections no more than 24 hours after receipt. If you will be unreachable at all during this period or anticipate any problems meeting this timeline, please contact Diana Oesterle, Issue Manager (doesterle@cell.com). |
4樓2015-03-08 16:53:57
下裡巴人
金蟲 (小有名氣)
- 博學(xué)EPI: 1
- 應(yīng)助: 4 (幼兒園)
- 金幣: 937.6
- 紅花: 1
- 帖子: 84
- 在線: 95.3小時(shí)
- 蟲號(hào): 1382419
- 注冊(cè): 2011-08-28
- 性別: GG
- 專業(yè): 催化化學(xué)
【答案】應(yīng)助回帖
» 本帖已獲得的紅花（最新10朵）
cclandrover2樓2015-03-08 15:53:10
cclandrover
新蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 9
- 散金: 5
- 帖子: 14
- 在線: 12.3小時(shí)
- 蟲號(hào): 2841528
- 注冊(cè): 2013-12-02
3樓2015-03-08 16:20:42
cclandrover
新蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 9
- 散金: 5
- 帖子: 14
- 在線: 12.3小時(shí)
- 蟲號(hào): 2841528
- 注冊(cè): 2013-12-02
5樓2015-03-08 17:27:34
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 281求調(diào)劑（0805） +13 | 煙汐憶海 2026-03-16 | 24/1200 |
|
|---|---|---|---|---|
|
|
[考研] 265求調(diào)劑 +8 | 梁梁校校 2026-03-17 | 8/400 |
|
|
|
[考研] 265求調(diào)劑 +9 | 梁梁校校 2026-03-19 | 9/450 |
|
|
[考博] 招收博士1-2人 +3 | QGZDSYS 2026-03-18 | 3/150 |
|
|
|
[考研] 一志愿西南交通 專碩 材料355 本科雙非 求調(diào)劑 +4 | 西南交通專材355 2026-03-19 | 4/200 |
|
|
|
[考研] 286分人工智能專業(yè)請(qǐng)求調(diào)劑愿意跨考！ +3 | lemonzzn 2026-03-17 | 4/200 |
|
|
|
[考研] 304求調(diào)劑 +5 | 曼殊2266 2026-03-18 | 5/250 |
|
|
|
[考研] 一志愿南京理工大學(xué)085701資源與環(huán)境302分求調(diào)劑 +3 | 葵梓衛(wèi)隊(duì) 2026-03-18 | 5/250 |
|
|
|
[考研] 復(fù)試調(diào)劑 +4 | z1z2z3879 2026-03-14 | 6/300 |
|
|
|
[考研] 085601材料工程專碩求調(diào)劑 +10 | 慕寒mio 2026-03-16 | 10/500 |
|
|
|
[考研] 一志愿中海洋材料工程專碩330分求調(diào)劑 +7 | 小材化本科 2026-03-18 | 7/350 |
|
|
|
[考研] 一志愿天大材料與化工（085600）總分338 +5 | 蔡大美女 2026-03-13 | 5/250 |
|
|
|
[考研] 328求調(diào)劑，英語六級(jí)551，有科研經(jīng)歷 +3 | 生物工程調(diào)劑 2026-03-17 | 7/350 |
|
|
|
[考研] 299求調(diào)劑 +5 | △小透明* 2026-03-17 | 5/250 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
|
[考研] 301求調(diào)劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
|
[考研] 085601求調(diào)劑 +4 | Du.11 2026-03-16 | 4/200 |
|
|
|
[考研] 藥學(xué)383 求調(diào)劑 +3 | 藥學(xué)chy 2026-03-15 | 4/200 |
|
|
|
[基金申請(qǐng)]
今年的國(guó)基金是打分制嗎？
 50+3
|
zhanghaozhu 2026-03-14 | 3/150 |
|
|
|
[考研] 326求調(diào)劑 +3 | mlpqaz03 2026-03-15 | 3/150 |
|